--(BUSINESS WIRE)--MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology and acute care. MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.
